$105 Million is the total value of Syncona Portfolio Ltd's 4 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q1 2022 |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Syncona Holdings Limited #1
- Syncona Limited #2
- Syncona Investment Management Limited #3
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-31
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
AUTOLUS THERAPEUTICS PLC | 8 | Q3 2023 | 76.6% |
ACHILLES THERAPEUTICS PLC | 8 | Q3 2023 | 53.1% |
FREELINE THERAPEUTICS HLDGS | 8 | Q3 2023 | 27.4% |
ADAPTIMMUNE THERAPEUTICS PLC | 8 | Q3 2023 | 4.9% |
View Syncona Portfolio Ltd's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Freeline Therapeutics Holdings plc | March 25, 2022 | 37,862,147 | 62.3% |
Nightstar Therapeutics plc | March 14, 2019 | 13,203,922 | 39.0% |
View Syncona Portfolio Ltd's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-07 |
SC 13D/A | 2024-02-22 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
13F-HR | 2024-02-01 |
SC 13D/A | 2023-11-24 |
13F-HR | 2023-11-01 |
SC 13D/A | 2023-10-18 |
13F-HR | 2023-07-27 |
13F-HR | 2023-05-12 |
View Syncona Portfolio Ltd's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.